Tretinoin cream to prevent skin rash from EGFR drugs
Part of Cancer clinical trials.
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have an advanced solid tumor (spread locally or to other parts of the body).
- Be scheduled to receive panitumumab or cetuximab as standard care.
- Be in fairly good physical condition (ECOG score 0–2).
- Have adequate liver and kidney function (specific lab results needed).
- Not have taken an anti-EGFR drug in the past 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
This Phase 2 study tests a topical cream (HT-001) to treat skin rashes caused by EGFR inhibitors. It aims to see whether the cream is safe and can reduce rash symptoms and discomfort.
This trial tests a new gel (TAR-0520) for treating a bothersome, acne-like rash that often occurs on the face, scalp, or upper chest during cancer treatment with cetuximab or panitumumab. The goal is to see if it helps reduce the rash without affecting your cancer treatment.
This trial tests a new cream called ATR04-484 to see if it can help with the painful rash that often appears on the face and chest during EGFR inhibitor cancer treatment. The cream is applied to the skin, with the goal of reducing redness, bumps, and discomfort.
This trial tests a combination of a targeted antibody (cetuximab beta) with a type of radiation and immunotherapy for people with advanced solid tumors that have the EGFR protein. It is for patients who have tried other treatments without success.
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.